4.6 Article

T lymphocytes as dynamic regulators of glioma pathobiology

Journal

NEURO-ONCOLOGY
Volume 24, Issue 10, Pages 1647-1657

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/noac055

Keywords

astrocytoma; glioblastoma; gliomagenesis; microglia; pediatric low-grade glioma; T cells; tumor microenvironment; tumor-associated monocytes

Funding

  1. Schnuck Markets, Inc.
  2. DeNardo Research and Education Foundation at the Washington University School of Medicine
  3. National Institutes of Health [R37-NS094804, R01-NS105556, R21-NS107894, RO1 NS122536, R21 NS123879, 1-R35-NS07211-01]
  4. Rogel Cancer Center Scholar Award
  5. Forbes Foundation Award
  6. Pediatric Brain Tumor Foundation
  7. Leah's Happy Hearts Foundation
  8. Chad Tough Foundation
  9. Ian's Friends Foundation
  10. National Institutes of Health/National Cancer Institute [T32-CA009676]
  11. Smiles for Sophie Forever Foundation

Ask authors/readers for more resources

The brain tumor microenvironment contains various nonneoplastic cells, which play important roles in the formation and progression of brain cancers. This review discusses the roles of T cells in low- and high-grade glioma formation and progression, as well as the potential uses of modified T lymphocytes for brain cancer therapeutics.
The brain tumor microenvironment contains numerous distinct types of nonneoplastic cells, which each serve a diverse set of roles relevant to the formation, maintenance, and progression of these central nervous system cancers. While varying in frequencies, monocytes (macrophages, microglia, and myeloid-derived suppressor cells), dendritic cells, natural killer cells, and T lymphocytes represent the most common nonneoplastic cellular constituents in low- and high-grade gliomas (astrocytomas). Although T cells are conventionally thought to target and eliminate neoplastic cells, T cells also exist in other states, characterized by tolerance, ignorance, anergy, and exhaustion. In addition, T cells can function as drivers of brain cancer growth, especially in low-grade gliomas. Since T cells originate in the blood and bone marrow sinuses, their capacity to function as both positive and negative regulators of glioma growth has ignited renewed interest in their deployment as immunotherapeutic agents. In this review, we discuss the roles of T cells in low- and high-grade glioma formation and progression, as well as the potential uses of modified T lymphocytes for brain cancer therapeutics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available